Fulcrum Therapeutics Inc. (FULC) Prices 6.6M Share Offering at $19/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Fulcrum Therapeutics (FULC) PT Raised to $12 at BofA Securities
August 11, 2021 6:01 AM EDTBofA Securities analyst Tazeen Ahmad raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $12.00 (from $11.00) while maintaining a Underperform rating.... More
UPDATE: Morgan Stanley Upgrades Fulcrum Therapeutics (FULC) to Overweight
August 11, 2021 3:27 AM EDT(Updated - August 11, 2021 5:49 AM EDT)
Morgan Stanley analyst Matthew Harrison upgraded Fulcrum Therapeutics (NASDAQ: FULC) from Equalweight to Overweight with a price target of $34.00 (from $12.00).
The analyst comments " Despite the ~125% increase in valuation today,FULC still only has an EV of... More
Fulcrum Therapeutics Inc. (FULC) Announces $100M Proposed Public Offering of Common Stock
August 10, 2021 4:24 PM EDTFulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares... More
Fulcrum Therapeutics (FULC) PT Raised to $30 at Credit Suisse
August 10, 2021 4:17 PM EDTCredit Suisse analyst Judah C. Frommer raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $30.00 (from $20.00) while maintaining a Outperform rating.... More
Fulcrum Therapeutics' (FULC) FTX-6058 Data is Strong Start, Sets Stage for In-Patient Trial in 4Q21 - Analyst
August 10, 2021 1:34 PM EDTEarlier today, Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced positive interim results from its ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy adult volunteers.
Results from the MAD portion of the trial demonstrated proof of biology as evidenced by a dose proportional induction in HBG mRNA and accompanying increases in HbF-containing reticulocytes... More
Fulcrum Therapeutics Inc. (FULC) Halted on LUDP, Up 114%
August 10, 2021 11:27 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) Halted on LUDP, Up 114%
Fulcrum Therapeutics (FULC) PT Raised to $45 at Stifel
August 10, 2021 11:00 AM EDTStifel analyst Dae Gon Ha raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $45.00 (from $39.00) while maintaining a Buy rating.
... MoreFulcrum Therapeutics Inc. (FULC) Climbs 48%
August 10, 2021 8:29 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) Climbs 48%
Earlier Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease... MoreFulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
August 10, 2021 7:07 AM EDTFulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced positive interim results from the ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy adult volunteers. FTX-6058 is an investigational, potent, and selective small molecule inhibitor of EED designed to... More
